Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. Historically, the California-based pharma has remained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback